Mitochondrial Complex I Dysfunction in Progressive Supranuclear Palsy

Mitochondrial Complex I Dysfunction in Progressive Supranuclear Palsy

Overview

Progressive supranuclear palsy (PSP) is a 4R-tauopathy characterized by the accumulation of hyperphosphorylated [tau protein](/proteins/tau) in the basal ganglia, brainstem, and frontal [cortex](/brain-regions/cortex). While tau pathology is the defining feature of PSP, emerging evidence demonstrates that mitochondrial dysfunction, particularly Complex I (NADH:ubiquinone oxidoreductase) deficiency, represents a critical secondary pathological mechanism that contributes to neuronal vulnerability and disease progression.[@cummins2019]

Complex I is the largest and most complex enzyme of the mitochondrial electron transport chain (ETC), containing 44 subunits and catalyzing the transfer of electrons from NADH to ubiquinone.[@shoffner1991] This process is fundamental to oxidative phosphorylation and ATP production. In PSP, selective Complex I deficiency has been documented in the substantia nigra and striatum, regions prominently affected by both tau pathology and neuronal loss [1](https://pubmed.ncbi.nlm.nih.gov/10987850/).

This mechanism page examines the evidence for Complex I dysfunction in PSP, its relationship to tau pathology, comparisons with Parkinson's disease mitochondrial pathology, mitochondrial DNA considerations, oxidative stress mechanisms, and therapeutic implications.

Evidence for Complex I Deficiency in PSP

Post-Mortem Neurochemistry Studies

Mitochondrial Complex I Dysfunction in Progressive Supranuclear Palsy

Overview

Progressive supranuclear palsy (PSP) is a 4R-tauopathy characterized by the accumulation of hyperphosphorylated [tau protein](/proteins/tau) in the basal ganglia, brainstem, and frontal [cortex](/brain-regions/cortex). While tau pathology is the defining feature of PSP, emerging evidence demonstrates that mitochondrial dysfunction, particularly Complex I (NADH:ubiquinone oxidoreductase) deficiency, represents a critical secondary pathological mechanism that contributes to neuronal vulnerability and disease progression.[@cummins2019]

Complex I is the largest and most complex enzyme of the mitochondrial electron transport chain (ETC), containing 44 subunits and catalyzing the transfer of electrons from NADH to ubiquinone.[@shoffner1991] This process is fundamental to oxidative phosphorylation and ATP production. In PSP, selective Complex I deficiency has been documented in the substantia nigra and striatum, regions prominently affected by both tau pathology and neuronal loss [1](https://pubmed.ncbi.nlm.nih.gov/10987850/).

This mechanism page examines the evidence for Complex I dysfunction in PSP, its relationship to tau pathology, comparisons with Parkinson's disease mitochondrial pathology, mitochondrial DNA considerations, oxidative stress mechanisms, and therapeutic implications.

Evidence for Complex I Deficiency in PSP

Post-Mortem Neurochemistry Studies

Biochemical studies of post-mortem PSP brain tissue have consistently identified reduced Complex I activity in affected regions:[@schapira1990]

| Brain Region | Complex I Deficiency | Reference |
|--------------|---------------------|-----------|
| Substantia nigra | 25-35% reduction | [1](https://pubmed.ncbi.nlm.nih.gov/10987850/) |
| Striatum (caudate/putamen) | 20-30% reduction | [1](https://pubmed.ncbi.nlm.nih.gov/10987850/) |
| Globus pallidus | 15-25% reduction | [2](https://pubmed.ncbi.nlm.nih.gov/26141487/) |
| Frontal cortex | Variable, often minimal | [1](https://pubmed.ncbi.nlm.nih.gov/10987850/) |

The regional pattern of Complex I deficiency in PSP closely parallels the distribution of tau pathology, with the most severe deficits in brain regions showing the highest tau burden. This correlation suggests that tau pathology may directly or indirectly impair mitochondrial function [3](https://pubmed.ncbi.nlm.nih.gov/30940747/).

Comparison with Parkinson's Disease

PSP and Parkinson's disease both demonstrate mitochondrial Complex I deficiency, but important distinctions exist:

The shared mitochondrial dysfunction between PSP and PD provides a biological rationale for testing mitochondrial-supportive therapies developed for PD in PSP patients. However, the distinct proteinopathies (alpha-synuclein vs. 4R-tau) suggest that the underlying mechanisms of mitochondrial impairment may differ.

Molecular Mechanisms of Complex I Dysfunction in PSP

Direct Tau-Complex I Interaction

Recent research has demonstrated that hyperphosphorylated tau protein can directly interact with Complex I subunits, particularly NDUFS1 (NADH:ubiquinone oxidoreductase core subunit S1). This interaction reduces electron transport chain activity by approximately 25-30% in post-mortem PSP brain tissue [3](https://pubmed.ncbi.nlm.nih.gov/30940747/).

The NDUFS1 subunit belongs to the matrix arm of Complex I and contributes to the proximal electron-transfer module that accepts electrons from NADH and transmits them through iron-sulfur centers toward ubiquinone reduction. Tau-mediated disruption of this process impairs the catalytic efficiency of Complex I and increases electron leak [4](https://pubmed.ncbi.nlm.nih.gov/38356254/).

Mitochondrial Transport Impairment

PSP tau pathology disrupts microtubule-based axonal transport, which is essential for mitochondrial trafficking to energy-demanding synaptic terminals. Affected neurons accumulate dysfunctional mitochondria in the cell body while distal synapses experience energy deprivation. This mechanism creates a bidirectional relationship where tau impairs transport, leading to mitochondrial dysfunction, which then exacerbates tau pathology through energy-dependent phosphorylation defects [5](https://pubmed.ncbi.nlm.nih.gov/29381127/).

Mitochondrial Dynamics Imbalance

Tau overexpression and aggregation disrupts the balance between mitochondrial fission and fusion [3](https://pubmed.ncbi.nlm.nih.gov/30940747/):

• Increased fission: Tau activates DRP1 (dynamin-related protein 1)-mediated mitochondrial division, producing fragmented mitochondria with impaired respiratory function
• Decreased fusion: Tau interferes with mitofusin (MFN1/2) and OPA1 function, reducing the ability of mitochondria to fuse and share components
• Network fragmentation: The resulting fragmented mitochondrial network cannot meet the energy demands of high-firing neurons in the basal ganglia and brainstem

Mitophagy Pathway Dysfunction

The PINK1/Parkin mitophagy pathway, which normally clears damaged mitochondria, is impaired in PSP through multiple mechanisms [3](https://pubmed.ncbi.nlm.nih.gov/30940747/):

Mitochondrial DNA Considerations

Mitochondrial DNA (mtDNA) mutations and deletions accumulate with age and may contribute to Complex I dysfunction in PSP [6](https://doi.org/10.1016/j.tins.2017.05.005):

• Somatic mtDNA mutations: neurons in PSP substantia nigra show increased mtDNA deletion burden compared to age-matched controls
• Compromised mitochondrial biogenesis: PGC-1α (PPARGC1A) expression is reduced in PSP brain tissue, impairing the cell's ability to generate new healthy mitochondria
• Aging interaction: The normal age-related decline in mitochondrial function may synergize with disease-specific tau pathology to accelerate neurodegeneration

Oxidative Stress Consequences

Complex I dysfunction leads to increased reactive oxygen species (ROS) production through several mechanisms:

The oxidative stress in PSP brain tissue is compounded by [7](https://doi.org/10.1038/nature04782):

• Reduced antioxidant defenses (glutathione, SOD, catalase)
• Iron accumulation in the basal ganglia
• Neuromelanin oxidation in substantia nigra neurons

Regional Vulnerability Patterns

Substantia Nigra Pars Compacta

The substantia nigra in PSP shows the most severe Complex I deficiency [1](https://pubmed.ncbi.nlm.nih.gov/10987850/), contributing to:

• Accelerated dopaminergic neuron loss
• Parkinsonian features (bradykinesia, rigidity)
• The characteristic supranuclear gaze palsy results from oculomotor nucleus involvement

Striatum (Caudate and Putamen)

Striatal Complex I dysfunction contributes to:

• GABAergic neuron vulnerability
• Movement initiation deficits
• The progressive gait disturbance and postural instability characteristic of PSP

Globus Pallidus

Pallidal Complex I deficiency exacerbates:

• Inhibitory output dysregulation
• Network-level oscillatory abnormalities
• The rigid-axial phenotype predominant in PSP

Brainstem Nuclei

Multiple brainstem nuclei affected in PSP show mitochondrial vulnerability:

• Oculomotor nucleus (vertical gaze palsy)
• Pedunculopontine nucleus (gait instability)
• Red nucleus (motor coordination)
• Reticular formation (arousal, consciousness)

Cortical Regions

While the neocortex shows less prominent Complex I deficiency compared to subcortical structures, several cortical regions demonstrate mitochondrial abnormalities in PSP:

Frontal Cortex

• Variable Complex I activity reductions (0-20%)
• More prominent in patients with frontal lobe syndrome
• Tau pathology burden correlates with mitochondrial dysfunction
• Executive dysfunction in PSP may relate to frontal cortical energy failure

• Upper motor neuron involvement in PSP correlates with corticospinal tract degeneration
• Mitochondrial function supports the high metabolic demands of pyramidal neurons
• Reduced Complex I efficiency may contribute to the progressive motor decline

Relationship Between Tau Pathology and Mitochondrial Dysfunction

Bidirectional Pathological Loop

The relationship between tau pathology and mitochondrial dysfunction in PSP is characterized by a self-amplifying pathological loop:

This bidirectional loop creates a feed-forward mechanism where each pathological process accelerates the other. Understanding this relationship is crucial for developing effective therapeutic interventions that can break this cycle.

Molecular Mediators of Tau-Mitochondria Crosstalk

Several molecular pathways mediate the interaction between tau pathology and mitochondrial dysfunction:

[GSK-3β](/entities/gsk3-beta) Activation

• Energy depletion activates GSK-3β (glycogen synthase kinase-3 beta)
• Active GSK-3β phosphorylates tau at multiple sites
• Phosphorylated tau is more prone to aggregation
• This creates a self-reinforcing cycle of tau pathology and energy failure

• AMPK (AMP-activated protein kinase) senses cellular energy status
• ATP depletion activates AMPK
• Active AMPK attempts to restore energy balance through catabolism
• Chronic AMPK activation may have complex effects on tau pathology

• Energy failure impairs phosphatase activity
• Reduced [PP2A](/entities/pp2a) (protein phosphatase 2A) activity promotes tau phosphorylation
• The balance between kinases and phosphatases shifts toward hyperphosphorylation

Clinical Correlations

Motor Symptoms and Mitochondrial Dysfunction

The characteristic motor features of PSP correlate with regional mitochondrial dysfunction:

Parkinsonism (Bradykinesia, Rigidity)

• Substantia nigra Complex I deficiency directly impairs dopaminergic neuron function
• Dopaminergic [neurons](/entities/neurons) have exceptionally high energy demands
• ATP depletion leads to impaired dopamine synthesis and release

• Oculomotor nucleus depends on mitochondrial function for rapid firing
• The rostral interstitial nucleus of medial longitudinal fasciculus (riMLF) shows tau pathology
• Mitochondrial dysfunction in these nuclei contributes to gaze palsy

• Brainstem nuclei controlling posture and balance have high metabolic demands
• Globus pallidus dysfunction disrupts postural reflexes
• Mitochondrial failure compounds the effects of tau pathology

Cognitive Impairment and Energy Failure

The cognitive deficits in PSP (frontal executive dysfunction, behavioral changes) relate to mitochondrial dysfunction in several ways:

Prefrontal Cortex Vulnerability

• Executive functions require sustained neuronal activity
• Mitochondrial dysfunction impairs the energy-intensive processes of working memory
• Frontal cortex hypometabolism on FDG-PET correlates with executive dysfunction

• PSP disrupts prefrontal-striatal-thalamic circuits
• Mitochondrial dysfunction in any component disrupts the entire network
• Energy failure in basal ganglia contributes to executive impairment

Disease Progression Markers

Mitochondrial dysfunction may serve as a biomarker of disease progression:

Biochemical Markers

• Decreased Complex I activity in accessible tissues (platelets, fibroblasts)
• Increased oxidative stress markers in cerebrospinal fluid
• Altered mitochondrial DNA copy number in blood cells

• FDG-PET shows characteristic hypometabolism patterns
• MRS (magnetic resonance spectroscopy) can detect reduced NAA/Cr ratios
• PET ligands targeting mitochondrial function are under development

Therapeutic Implications

Mitochondrial Support Strategies

The evidence for Complex I dysfunction in PSP supports several therapeutic approaches:

| Strategy | Agent | Mechanism | Evidence Level |
|----------|-------|----------|----------------|
| Electron transfer | CoQ10 | Complex I/II to III electron shuttling | Moderate (PD trials) [8](https://doi.org/10.1016/j.tins.2018.08.005) |
| Electron carrier | Methylene blue | Alternative electron flow | Preclinical |
| Antioxidants | MitoQ, edaravone | Mitochondrial [ROS](/entities/reactive-oxygen-species) scavenging | Preclinical |
| Mitophagy enhancers | Urolithin A, rapamycin | Mitochondrial quality control | Early clinical |
| Metabolic support | Creatine, acetyl-L-carnitine | ATP buffer/transport | Moderate |
| NAD+ boosters | Nicotinamide riboside | SIRT activation, bioenergetics | Preclinical |

Clinical Trial Considerations

• Biomarker enrichment: Selecting patients with demonstrated mitochondrial dysfunction may improve trial sensitivity
• Combination approaches: Targeting multiple aspects of mitochondrial dysfunction (electron transfer, ROS, mitophagy) may be more effective than single mechanisms
• Early intervention: Mitochondrial dysfunction likely precedes overt clinical symptoms; early intervention may be more effective
• Duration of treatment: Given the chronic progressive nature of PSP, long-term treatment trials (12+ months) may be necessary to detect disease-modifying effects
• Outcome measures: Combining clinical measures (PSPRS, TUG, falls diary) with biomarkers (mitochondrial function assays, oxidative stress markers) may provide more sensitive endpoints

Detailed Therapeutic Approaches

Coenzyme Q10 (CoQ10)
CoQ10 serves as an essential electron shuttle in the mitochondrial electron transport chain, transferring electrons from Complex I and Complex II to Complex III [8](https://doi.org/10.1016/j.tins.2018.08.005). In PSP, CoQ10 supplementation may:

• Bypass impaired Complex I function by providing an alternative electron pathway
• Reduce electron leak and subsequent ROS production
• Support cellular antioxidant networks

Methylene Blue
Methylene blue acts as an alternative electron carrier that can donate electrons directly to Complex IV, bypassing damaged Complex I. This dual action makes it particularly attractive for PSP:

• Provides alternative electron flow pathway
• Reduces oxidative stress through its antioxidant properties
• May enhance mitochondrial function in neurons with Complex I deficiency

Mitophagy Enhancers (Urolithin A, Rapamycin)
Enhancing mitophagy may help clear damaged mitochondria in PSP:

• Urolithin A has been shown to improve mitophagy in preclinical models
• Rapamycin activates [autophagy](/entities/autophagy) through [mTOR](/mechanisms/mtor-signaling-pathway) inhibition
• These approaches may be particularly relevant given the tau-mediated mitophagy blockade

Metabolic Support (Creatine, Acetyl-L-Carnitine)
Supporting cellular energy metabolism may provide neuroprotection:

• Creatine maintains ATP levels by buffering phosphocreatine
• Acetyl-L-carnitine supports fatty acid transport into mitochondria
• Both compounds have favorable safety profiles in human studies

• SIRT1 activation promotes mitochondrial biogenesis
• NAD+ is required for PARP-mediated DNA repair
• Age-related NAD+ decline may compound mitochondrial dysfunction

Relationship to Tau-Targeted Therapy

Mitochondrial support may complement tau-directed therapies by:

• Improving neuronal energy reserves to support microtubule function
• Reducing oxidative stress that promotes tau phosphorylation
• Enhancing cellular clearance mechanisms
• Supporting the activity of microtubule-stabilizing agents

Cross-Links to Related Mechanisms

• [Mitochondrial Dysfunction in Neurodegeneration](/mechanisms/mitochondrial-dysfunction-neurodegeneration) — General mitochondrial mechanisms
• [Mitochondrial Dysfunction in Parkinson's Disease](/mechanisms/mitochondrial-dysfunction-parkinsons) — PD-specific findings
• [Tau Pathology Pathway](/mechanisms/tau-pathology-pathway) — Primary PSP pathology
• [4R-Tau in CBS/PSP](/mechanisms/4r-tau-cbs) — 4R-tau specificity
• [Oxidative Stress in Neurodegeneration](/mechanisms/oxidative-stress-neurodegeneration) — ROS consequences
• [Substantia Nigra Selective Vulnerability in Parkinson's Disease](/mechanisms/substantia-nigra-selective-vulnerability-parkinsons) — Regional vulnerability

Key Genes and Proteins

| Gene/Protein | Function | Relevance to PSP Mitochondria |
|--------------|----------|-------------------------------|
| NDUFS1 | Complex I core subunit | Direct tau interaction |
| PINK1 | Mitophagy kinase | Impaired in PSP |
| PRKN (Parkin) | E3 ubiquitin ligase | Sequestered by tau |
| PARP1 | DNA repair enzyme | Over-activated by ROS |
| PGC-1α | Mitochondrial biogenesis | Reduced in PSP |
| TFAM | mtDNA transcription | Compromised |

See Also

• [Mitochondrial Dysfunction in Neurodegeneration](/mechanisms/mitochondrial-dysfunction-neurodegeneration)
• [Mitochondrial Dysfunction in Parkinson's Disease](/mechanisms/mitochondrial-dysfunction-parkinsons)
• [Tau Pathology Pathway](/mechanisms/tau-pathology-pathway)
• [4R-Tau in CBS/PSP](/mechanisms/4r-tau-cbs)
• [Oxidative Stress in Neurodegeneration](/mechanisms/oxidative-stress-neurodegeneration)
• [Substantia Nigra Selective Vulnerability in Parkinson's Disease](/mechanisms/substantia-nigra-selective-vulnerability-parkinsons)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References